Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088415 | 0.85 | HPGD (0.42) | TP53ALOX15MAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL20094251 | 0.81 | POLB (0.42) | HSD17B10SMN1; SMN2HPGDCACNA1HCACNA1C | |
| SCHEMBL15844109 | 0.78 | CBFB (0.35) | CACNA1HCACNA1CCBFBCACNA1BCACNA1G | |
| SCHEMBL15844276 | 0.76 | CACNA1H (0.33) | CACNA1HCACNA1CCACNA1BCACNA1GNPBWR1 | |
| SCHEMBL15844369 | 0.74 | IKBKB (0.41) | MAPK1CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL15844443 | 0.74 | CACNA1H (0.35) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL12020771 | 0.73 | MAPT (0.42) | HSD17B10HPGDCACNA1HCACNA1CCACNA1B | |
| SCHEMBL15843907 | 0.70 | NPBWR1 (0.38) | CACNA1HCACNA1CCACNA1BNPBWR1 | |
| SCHEMBL15844178 | 0.70 | NPBWR1 (0.52) | CACNA1HCACNA1CCACNA1BNPBWR1 | |
| SCHEMBL8872748 | 0.70 | CACNA1H (0.39) | CACNA1HCACNA1CCACNA1BCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | TP53 4747/4885ALOX15 2997/4885MAPK1 1360/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | TP53 4747/4885ALOX15 2997/4885MAPK1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.